#Spain #Barcelona #Parkinson's Disease #Alzheimer's Disease #Neurodegenerative Research

AD/PD™ 2027 Conference: Innovating Neurodegeneration Research

The highly anticipated AD/PD™ 2027 conference, scheduled for March 16-20, 2027, in Barcelona, Spain, promises to be a pivotal event in the field of neurodegenerative disease research. Organized by the esteemed Kenes Group, this conference will bring together over 6,000 participants from more than 70 countries, showcasing 120 symposia featuring over 750 on-site talks and 1,500 posters, all aimed at advancing understanding and treatment of Alzheimer’s and Parkinson’s diseases.

Conference Highlights

The central theme of AD/PD™ 2027 is to advance early detection, disease mechanisms, and innovative therapies for neurodegenerative diseases. This year’s program focuses on crucial areas including:

• - Emerging Biomarkers: Discussions on novel blood-based biomarkers for Alzheimer’s detection and innovative techniques for identifying alpha-synuclein associated with Parkinson's disease.
• - Disease Mechanisms: Extensive research on genetic and environmental factors, indicating how inflammation, amyloid-beta toxicity, and tau pathology contribute to neurodegeneration.
• - Novel Therapeutic Approaches: A presentation of a range of therapies aimed at disease modification, including amyloid-beta immunotherapies, antibodies targeting tau, and strategies addressing cognitive dysfunction.

Professor Abraham Fisher, Co-founder and President of AD/PD™, expressed his excitement for the event, stating, “The convergence of increasingly sensitive biomarkers, deeper mechanistic insights, and a growing diversity of therapeutic approaches provide us a unique opportunity to evaluate these advances and how they translate into meaningful benefits for patients.”

Keynote Speakers

The conference will feature prominent voices in neurodegenerative research, including:

• - Randall Bateman, MD (Washington University School of Medicine): He will deliver the Don Price Memorial Lecture, discussing advancements in Alzheimer's treatment and the integration of AI in discovery processes.
• - Henrik Zetterberg, MD, PhD: He will share insights into fluid biomarkers for tau pathophysiology in Alzheimer's disease.
• - Brit Mollenhauer, MD: His talk will focus on multimodal biomarkers for prevention trials in PD, enhancing our understanding of early intervention strategies.
• - Bradley Hyman, MD, PhD: He will explore the molecular pathology of Lewy body diseases.
• - Rosa Rademakers, PhD: Discussing the potential of genetics in combating neurodegeneration, presenting a bridge between discovery and disease modification.
• - Beth Stevens, PhD (Harvard Medical School): She will present findings on how brain macrophages influence cognitive resilience, significantly impacting aging and disease outcomes.

A Future Focused on Innovation

AD/PD™ 2027 aims to provide a platform for researchers and clinicians to collaborate and exchange insights, enhancing their understanding of neurodegenerative diseases. With the scientific program built around three core pillars: Biomarkers, Disease Etiology, and Novel Therapies, this hybrid conference will provide comprehensive knowledge to improve clinical practices worldwide.

The event is structured to not only present cutting-edge scientific research but also facilitate networking among thought leaders, fostering collaborations that can lead to more effective treatments and interventions for those suffering from Alzheimer’s and Parkinson’s diseases. As we approach the registration deadline of December 9, 2026, interest in the conference is expected to surge, reflecting the growing momentum in this critical field of study.

To stay informed and register for the event, attendees are encouraged to visit the AD/PD official website where an interactive program is available. This year’s event represents a significant step toward improving the lives of countless individuals affected by neurodegenerative disorders through enhanced understanding and innovative therapeutic approaches.

We look forward to seeing you in Barcelona!